

OVERALL AIM: Implementation of actions that support the translation of basic into clinical research and beyond in PM

ACTIONS:

A.9 Development and implementation of high-throughput preclinical models
A.10 Implement translational programmes with shared access to, for example, genetically defined patient populations
A.11 Integrate actions aimed at supporting and developing research for clinical validation of pharmacogenomics . Global impact evaluations of these actions on health systems .
A.13 Support research for clinical trials - a three-level process
A.14 Longitudinal cohort studies of disease outcomes
A.15 Research in adequate regulatory structures and pathways in personalised medicine
B.2 Development and maintenance of biobanks and population/ disease cohorts
B.3 Establish a new collaborative funding organisation model with healthcare providers to facilitate investment in disease prevention research and therapy research
B.4 Develop common strategies in research to support comparative and effective research, and sustainable technology transfer capacities

Main activities:

1. Mapping activities on PM initiatives (including non-funding activities)
2. Selection of best practice example for ICPerMed
3. Suggestions for selecting topics within the *ERA PerMED call*.
4. Contribution to the ICPerMed State of the Art Report
5. Activities for the elaboration of reflection papers
6. Interactions with relevant experts and stakeholders to further promote and develop the field

Next Steps:

1. Prepare pilot best practice example for the ICPerMed website
2. Continue mapping and analyses
3. Collect and enhance experiences on clinical studies within PM

Participating members:

Institution	Country
Ministry of Education, Science and Research - BMBWF	Austria
VDI/VDE Innovation & Technik GmbH	Germany
Ministry of Health	Germany
DLR-Project Management Agency	Germany
Federal Institute for Drugs and Medical Devices - BfArM	Germany
Paul Ehrlich Institute for Vaccines and Biomedicines - PEI	Germany
Academy of Finland	Finland
Hungarian Society of Personalized Medicine	Hungary
Tehran University of Medical Sciences	Iran
Health Research Board	Ireland
Ministry of Health	Israel
Ministry of Health	Italy
National Research Council of Italy - CNR	Italy
State University of Medicine and Pharmacy Nicolae Testemitsanu	Moldova
The Netherlands Organisation for Health Research and Development - ZonMw	The Netherlands
Ministry of Science and Higher Education/Warsaw Medical University	Poland
Agency for Science and Technology - FCT	Portugal
National Institute of Health Dr. Ricardo Jorge - INSA	Portugal
Gobierno de Navarra	Spain
Swedish Research Council	Sweden
Vinnova – Swedish Innovation Agency	Sweden
Health Institute of Turkey	Turkey



Contact information:

Please contact the AIG 3 lead or ICPerMed Secretariat for all questions concerning AIG 3 and its activities.

hemma.bauer@bmbwf.gv.at
sebastian.delbrueck@vdivde-it.de
ICPerMed@dlr.de

